Coagulation Sciences is developing technology that will scientifically guide blood transfusion decisions. Such technology is sorely needed, as at least 30% of all administered blood transfusions are unnecessary.
Large amounts of bleeding, due to abnormalities in the blood, can significantly prolong the length of surgery. The more time required to arrest bleeding, the greater the cost, as operating rooms cost approximately $40 – $60 per minute. However, many insurance companies reimburse based upon procedure codes, not the length of surgery. Therefore, less time in the operating room translates into higher revenue for the hospital.
Traumatic coagulopathy is often present by the time accident victims reach the Emergency Room. Coagulation Sciences’ Multiple Coagulation Test System will allow physicians to determine within ten minutes the specific Blood products and pharmaceutical products that will be required to restore clotting to normal. This is especially important in trauma victims, as delay in treatment of traumatic coagulopathy results in higher mortality.
The MCTS will determine the optimal treatment and dose of therapy for patients with a multitude of bleeding disorders. Use of the MCTS will result in therapy that is individualized for each patient. This will be especially useful in hospitals that do not perform coagulation factor levels on a STAT basis.
Patients know that blood transfusions are associated with risks. Still, transfusions may be life-saving. Therefore, these risks often must be accepted. However, what is not commonly known is that 30% of administered blood transfusions are unnecessary. Coagulation Sciences MCTS will be the first fully automated Transfusion Management System. Though not all transfusions can be avoided, use of the MCTS will ensure those transfusions that are administered are truly necessary.
The Multiple Coagulation Test System may be used for research purposes to assess potency of anti-coagulants, and dose-response curves, in-vitro.